%0 Journal Article %A N Koufopoulos %A E Karopoulou %A A Arapaki %A K Strataki %A S Polykalas %A D Papatheodorou %T EP727 Presentation of the 14th case of leiomyoadenomatoid tumor in the english literature %D 2019 %R 10.1136/ijgc-2019-ESGO.780 %J International Journal of Gynecologic Cancer %P A411-A411 %V 29 %N Suppl 4 %X Introduction/Background Adenomatoid tumor (AT) is an uncommon benign tumor of mesothelial origin. It is most commonly encountered in the male and female genital tracts. Leiomyoadenomatoid tumor (LMAT) is a rare variant of AT with a prominent smooth muscle component. We present a case of LMAT.Methodology A 79 year-old woman without previous history was admitted to the department of gynaecology due to lower abdominal pain. Transvaginal ultrasonography revealed a 7.2 cm fibroid in the anterior wall of the uterine cervix. Hysterectomy and bilateral salpingo-oophorectomy was performed.On gross examination, besides the large leiomyoma of the uterine cervix a second intramural leiomyoma located in the antero-lateral wall of the corpus uteri was observed measuring 2.5 cm.On microscopic examination, both tumors consisted of smooth muscle bundles arranged in a fascicular pattern. In the smaller one, smooth muscle bundles were separated by slit-like and tubular structures lined by cuboidal epithelioid cells with small, uniform nuclei and scanty, pale, eosinophilic cytoplasm. Mitotic figures were not observed.Tumor cells were positive for AE-1/AE-3, CK-8/18, CK-7, Calretinin and negative for CD-31 and CD-34. SMA and Desmin highlighted smooth muscle cells. Ki-67 stained less than 1% of tumor nuclei.Results The morphological features as well as immunohistochemical results were consistent with LMAT of the uterus. On postoperative evaluation, three months after surgery, the patient shows no evidence of recurrence.Conclusion LMAT is a rare variant of AT with a prominent smooth muscle component. It was first described in 1992. Our literature review revealed 13 previously reported cases. Awareness of this rare entity is important in order to avoid misdiagnosis as adenocarcinoma.Disclosure Nothing to disclose. %U https://ijgc.bmj.com/content/ijgc/29/Suppl_4/A411.1.full.pdf